Neoadjuvant Chemotherapy Therapy Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck
Condition: Head and Neck Squamous Cell Carcinoma Interventions: Drug: Nab paclitaxel; Drug: Carboplatin; Drug: adelbelimumab Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
Condition: Sintilimab and Anlotinib in Combination With Chemotherapy Intervention: Drug: Sintilimab and anlotinib in combination with chemotherapy Sponsor: Tang-Du Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol
DiscussionWe designed this prospective single-arm phase II clinical study to evaluate the combination of camrelizumab and standard radiotherapy as preoperative neoadjuvant therapy for patients with resectable ESCC as part of the quest for better treatment options for patients with locally advanced ESCC.Trial registrationThis trial protocol has been registered on the NIH Clinical Trials database (www.clinicaltrials.gov/, NCT05176002. Registered on 2022/01/04). The posted information will be updated as needed to reflect protocol amendments and study progress. (Source: Trials)
Source: Trials - August 25, 2023 Category: Research Source Type: clinical trials

Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
Conditions: Oral Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma Interventions: Drug: Tislelizumab; Drug: Albumin-Bound Paclitaxel; Drug: Cisplatin Sponsor: Peking University Hospital of Stomatology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 24, 2023 Category: Research Source Type: clinical trials